Shots:
- Vividion (Bayer’s subsidiary) has acquired Tavros to strengthen its genomic capabilities via Tavros’ platform. The financial terms are undisclosed
- The acquisition strengthens Vividion’s functional genomics expertise by adding proprietary genomic screening approaches to discover new targets & translate the known ones. Combining resources from both the companies will enable drug discovery in oncology & immunology
- The acquisition was preceded by a 2yrs. strategic collaboration for the development of precision therapeutics targeting cancer-causing proteins
Ref: Bayer | Image: Tavros Therapeutics
Related News:- Vividion Therapeutics Commences P-I Study of VVD-130850 for Advanced Solid and Hematologic Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
